Stay updated with breaking news from Vertex Connects. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment - ...
Vertex and CRISPR Therapeutics have announced FDA approval for CASGEVY in treating sickle cell disease. Utilizing cutting edge CRISPR/Cas9 gene editing technology, a patient’s own genes are extracted, edited, and then reinserted to eliminate sickle cell in this new therapy.
– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. –– Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment –– Multiple authorized treatment centers activated –BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Ph...